Stock Track | Hengrui Pharma Plummets 5.01% Intraday on Dual Policy Headwinds from US COINS Act and China Export Controls

Stock Track06-03

Hengrui Pharma's stock plummeted 5.01% intraday, extending recent losses as investors continue to grapple with regulatory uncertainties affecting the innovative pharmaceutical sector.

The decline reflects mounting concerns over dual policy pressures from both the United States and China. On the US side, the House Select Committee on China has formally urged the Treasury to add biotechnology to the COINS Act prohibited investment list, explicitly naming Hengrui's $15.2 billion co-development deal with Bristol-Myers Squibb as a case of American capital empowering Chinese biotech. Simultaneously, a draft revision to China's Prohibited and Restricted Export Technology Catalogue reportedly seeks to restrict outbound transfers of core platform technologies in antibodies, ADCs, and gene therapy.

Although Hengrui has stated that its Co-Co collaboration model does not involve full technology ownership transfer and operations remain normal, investor sentiment has remained fragile amid these persistent policy uncertainties. The broader pharmaceuticals sector saw widespread weakness in response to these regulatory headwinds.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144806977?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 13:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144806977","market":"us","top_or_hot":-1,"title":"Stock Track | Hengrui Pharma Plummets 5.01% Intraday on Dual Policy Headwinds from US COINS Act and China Export Controls","media":"Stock Track","content":"<p>Hengrui Pharma's stock plummeted 5.01% intraday, extending recent losses as investors continue to grapple with regulatory uncertainties affecting the innovative pharmaceutical sector.</p><p>The decline reflects mounting concerns over dual policy pressures from both the United States and China. On the US side, the House Select Committee on China has formally urged the Treasury to add biotechnology to the COINS Act prohibited investment list, explicitly naming Hengrui's $15.2 billion co-development deal with Bristol-Myers Squibb as a case of American capital empowering Chinese biotech. Simultaneously, a draft revision to China's Prohibited and Restricted Export Technology Catalogue reportedly seeks to restrict outbound transfers of core platform technologies in antibodies, ADCs, and gene therapy.</p><p>Although Hengrui has stated that its Co-Co collaboration model does not involve full technology ownership transfer and operations remain normal, investor sentiment has remained fragile amid these persistent policy uncertainties. The broader pharmaceuticals sector saw widespread weakness in response to these regulatory headwinds.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hengrui Pharma Plummets 5.01% Intraday on Dual Policy Headwinds from US COINS Act and China Export Controls</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hengrui Pharma Plummets 5.01% Intraday on Dual Policy Headwinds from US COINS Act and China Export Controls\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-03 13:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hengrui Pharma's stock plummeted 5.01% intraday, extending recent losses as investors continue to grapple with regulatory uncertainties affecting the innovative pharmaceutical sector.</p><p>The decline reflects mounting concerns over dual policy pressures from both the United States and China. On the US side, the House Select Committee on China has formally urged the Treasury to add biotechnology to the COINS Act prohibited investment list, explicitly naming Hengrui's $15.2 billion co-development deal with Bristol-Myers Squibb as a case of American capital empowering Chinese biotech. Simultaneously, a draft revision to China's Prohibited and Restricted Export Technology Catalogue reportedly seeks to restrict outbound transfers of core platform technologies in antibodies, ADCs, and gene therapy.</p><p>Although Hengrui has stated that its Co-Co collaboration model does not involve full technology ownership transfer and operations remain normal, investor sentiment has remained fragile amid these persistent policy uncertainties. The broader pharmaceuticals sector saw widespread weakness in response to these regulatory headwinds.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1144806977","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144806977","pubTimestamp":1780463121,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hengrui Pharma's stock plummeted 5.01% intraday, extending recent losses as investors continue to grapple with regulatory uncertainties affecting the innovative pharmaceutical sector.The decline...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"个股轨迹|恒瑞医药盘中暴跌5.01%美国COINS法案和中国出口管制双重政策逆风","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"Hengrui Pharma's stock plummeted 5.01% intraday, extending recent losses as investors continue to grapple with regulatory uncertainties affecting the innovative pharmaceutical sector.The decline reflects mounting concerns over dual policy pressures from both the United States and China. On the US side, the House Select Committee on China has formally urged the Treasury to add biotechnology to the COINS Act prohibited investment list, explicitly naming Hengrui's $15.2 billion co-development deal with Bristol-Myers Squibb as a case of American capital empowering Chinese biotech. Simultaneously, a draft revision to China's Prohibited and Restricted Export Technology Catalogue reportedly seeks to restrict outbound transfers of core platform technologies in antibodies, ADCs, and gene therapy.Although Hengrui has stated that its Co-Co collaboration model does not involve full technology ownership transfer and operations remain normal, investor sentiment has remained fragile amid these persistent policy uncertainties. The broader pharmaceuticals sector saw widespread weakness in response to these regulatory headwinds.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144806977","isCrawlerRequest":true}